A Portfolio
of Anti-TB Drug
Candidates
The
TB Alliance's
international
mandate is to
accelerate and
ensure the development
of new, faster-acting
drugs that will
revolutionize
TB control.
The TB
Alliance's objective
is to develop
an entirely
new therapeutic
regimen that
will shorten
and simplify
treatment. A
shorter TB regimen
will improve
patient compliance,
increase cure
rates and lower
toxic side effects.
Our goal is
to deliver a
novel two-month
regimen which
can: 
Shorten the
duration of
tuberculosis
treatment or
otherwise simplify
its completion;
Be effective
against multi-drug
resistant tuberculosis
(MDR-TB);
Improve the
treatment of
latent tuberculosis,
and
Be compatible
with HIV treatment.
The
TB Alliance's
portfolio is
the first, most
comprehensive
TB drug pipeline
since the 1960s.
We actively
scout the world
for potential
TB drugs and
we take the
lead where selected
technology is
needed to move
forward. (See
Methodology
section for
more on selection
process.)
The TB
Alliance invests
in its own pipeline
and platform
technologies
that help streamline
the development
process, and
we support the
efforts and
work closely
with other TB
drug sponsors.
(see links on
other drug sponsors)
Reaching
Patients
The final test
of our efforts
is to ensure
that the optimal
new drug combination
reaches patients.
This principle
is reflected
in the TB Alliance's
AAA strategy:
the TB Alliance
works to ensure
that drugs are
affordable,
adopted by health
practitioners
and are accessible
to patients
who need them
most.
Affordability
— The affordability
of the final
product depends
on developments
costs and business
factors. We
identify classes
of compounds
that can be
developed, synthesized
and manufactured
in a cost-effective
way, to ensure
that the entire
drug development
process results
in affordable
drugs. We also
ensure that
agreements limit
royalties in
TB-endemic countries
and negotiate
commitments
to affordable
pricing.
Adoption
— Even at
drug design
stages, we consult
with key stakeholders,
experts and
TB program managers
of endemic countries
to ensure early
adoption. We
established
the characteristics
of the target
drug, such as
simple (oral)
administration
and compatibility
with antiretroviral
drugs. The TB
Alliance is
also working
closely with
the WHO, national
TB control programs,
and the Global
Fund for AIDS,
TB and Malaria
to ensure that
new drugs are
incorporated
into existing
treatment programs.
Access
— This is the
culmination
and final test
of the AAA strategy,
and the stage
where the drugs
are finally
delivered to
the patient.
Building on
affordability
and adoption,
access also
factors in the
distribution
channels including
national TB
programs, private
providers, patient
networks and
community-based
initiatives. |
|
|
